Final Data Analysis for Omacetaxine in Chronic, Accelerated Phase Chronic Myeloid Leukemia
the Cancer Therapy Advisor take:
Patients with chronic phase or accelerated phase chronic myeloid leukemia that is resistant and/or intolerant to two or more tyrosine kinase inhibitors can currently receive omacetaxine, a protein synthesis inhibitor.
The final analysis of omacetaxine, which included 24 months of follow-up, revealed additional safety and efficacy information to demonstrate the benefit of long-term omacetaxine administration in patients with chronic phase or accelerated phase chronic myeloid leukemia who received more than 3 cycles of treatment (1.25 mg/m2 twice daily for 14 days every 28 days followed by 7 days every 28 days).
The data showed that 18% of patients with chronic phase chronic myeloid leukemia achieved a major cytogenetic response that lasted a median of 12.5 months. The responses lasted for 12 months or more in three of 14 responders, and the rate of overall survival was a media of 40.3 months (95% CI, 23.8 months to NR). In patients with accelerated phase chronic myeloid leukemia, 14% of patients had a major hematologic response for a median of 4.7 months (95% CI, 3.6 months to NR).
In patients with accelerated phase chronic myeloid leukemia a major cytogenetic response was not seen and there was a median overall survival of 14.3 months (95% CI, 6.7, 18.7 months). There were 50 patients with chronic phase chronic myeloid leukemia who received more than 3 cycles of treatment and 14 patients with accelerated phase chronic myeloid leukemia who received more than 3 cycles of treatment. The median overall survival in these groups were 49.3 months (95% CI, 23.8 months to not reached) and 24.6 months (95% CI, 12, 37.2 months), respectively.
The most prominent side effects were grade 3 or higher hematologic toxicities (79% and 73% for chronic phase chronic myeloid leukemia and accelerated phase chronic myeloid leukemia, respectively). Ten percent of patients with chronic phase disease discontinued treatment because of toxicity and 5% of accelerated phase patients discontinued treatment because of toxicity.
Patients with chronic myeloid leukemia that is resistant to two or more tyrosine kinase inhibitors can currently receive omacetaxine.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin on Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer